02:30 PM EDT, 04/29/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We trim our target to $276 from $293, 17.2x our 2025 EPS estimate, a premium to historical due to a higher expected growth outlook. We lift our 2025 EPS view by $0.03 to $16.06 and 2026's by $0.09 to $17.64. LH reported Q1 EPS of $3.84 vs. $3.68, an $0.11 consensus beat. Q1 revenue grew 5.3% Y/Y to $3.35B, driven by strong performance in the core Diagnostics Laboratories business with 6.0% Y/Y growth boosted by acquisitions. However, operating margin contracted 20 bps due to the integration of recent acquisitions and weather-related impacts in the Diagnostics Laboratories business, partially offset by margin expansion in the Biopharma Laboratory Services segment due to savings from the LaunchPad initiative. Labcorp's ( LH ) management raised the midpoint of its EPS guidance by $0.05. In our view, this outlook suggests continued momentum in both segments and confidence in LH's ability to execute its growth strategy, through acquisitions, partnerships, and expansion of its test menu in key strategic areas.